Patents Assigned to Beth Israel Deaconess Medical Center, Inc.
  • Methods and devices for safely penetrating materials
    Patent number: 9561544
    Abstract: The present invention is directed to a bi-stable coupling for controlling the depth of a tool insertion, such as drilling, and similar processes. The bi-stable coupling can be used to penetrate (e.g., drill or push) through a material layer of unknown thickness without plunging the tool into the adjacent layer. In accordance with the invention, in a first state, force is applied to the tool to initiate penetration and a reactive force maintains the device in the first state during penetration and when tool penetrates the material, the reactive force is diminished enabling the device to transition to a second state in which the tool becomes retracted. In medical applications, the invention allows for drilling through bone of unknown thickness without plunging into the adjacent soft tissue.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: February 7, 2017
    Assignees: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Conor James Walsh, Ajith Thomas, Samuel Benjamin Kesner, Hao Pei, Kechao Xiao, Paul Loschak, Kevin C. Galloway
  • DIFFERENTIATION OF STEM CELLS INTO THYROID TISSUE
    Publication number: 20170027994
    Abstract: Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 2, 2017
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Darrell Kotton, Maria S. Serra, Anthony N. Hollenberg, Anita A. Kurmann
  • Diagnosis, prognosis, and treatment of kidney disease
    Patent number: 9549964
    Abstract: The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: January 24, 2017
    Assignees: Beth Israel Deaconess Medical Center, Inc., The General Hospital Corporation
    Inventors: Anders H. Berg, S. Ananth Karumanchi, Ravi I. Thadhani
  • ELECTRICAL IMPEDANCE MYOGRAPHY
    Publication number: 20170007151
    Abstract: Electrical impedance myography (EIM) can be used for assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and modeling one or more impedance metrics as a function of frequency may provide impedance model parameters that can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
    Type: Application
    Filed: February 13, 2015
    Publication date: January 12, 2017
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Seward B. RUTKOVE, Benjamin Sanchez TERRONES
  • Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
    Patent number: 9539323
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 10, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Kits for the diagnosis of pre-eclampsia or eclampsia
    Patent number: 9518992
    Abstract: Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 13, 2016
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Vikas P. Sukhatme
  • Vitamin D receptor agonists and uses thereof
    Patent number: 9499488
    Abstract: This invention features vitamin D receptor agonists, and their use in treating bone disorders, cardiovascular disease, hyperparathyroidism, immune disorders, proliferative disease, renal disease, and thrombosis.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 22, 2016
    Assignees: Beth Israel Deaconess Medical Center, Inc., The General Hospital Corporation
    Inventors: Peter M. Kang, S. Ananth Karumanchi, Santosh Khedkar, Alan Rigby, Ravi I. Thadhani
  • Biomarkers and treatments for heart failure
    Patent number: 9493838
    Abstract: The invention features methods to predict the response to a cardiac therapy in a patient suffering from a cardiac disease, e.g., heart failure. The invention features measurement expression of biomarkers that help in this prediction. The invention also features methods for treatment of cardiac diseases. These methods include cardiac resynchronization therapy and miRNA based therapeutics.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 15, 2016
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Saumya Das
  • Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
    Patent number: 9493813
    Abstract: The invention features methods for identifying compounds that modulate the activity of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K). Inhibitors of PI5P4K can be used in, for example, the treatment or prevention of cell proliferation disorders (e.g., the prevention of tumor cell growth in p53 mutated cancers).
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: November 15, 2016
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Brooke Emerling, Atsuo Sasaki, Lewis C. Cantley, Jonathan Hurov
  • Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
    Patent number: 9458227
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: October 4, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Methods for the treatment of immune disorders
    Patent number: 9439884
    Abstract: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: September 13, 2016
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Adrian Tun-Kyi, Greg Finn
  • Compounds and methods for treating diseases mediated by protease activated receptors
    Patent number: 9422262
    Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 23, 2016
    Assignees: The Broad Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Chris Dockendorff, Robert Flaumenhaft
  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Patent number: 9382286
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: July 5, 2016
    Assignees: EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING A DNA REPAIR VARIANT POLYPEPTIDE
    Publication number: 20160160291
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Application
    Filed: November 16, 2015
    Publication date: June 9, 2016
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: RALPH SCULLY, NICHOLAS A. WILLIS
  • TIM-3 ligands and methods of modulating immune responses
    Patent number: 9346876
    Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 24, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vijay K. Kuchroo, Terry Barton Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Anne Sabatos-Peyton, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
  • METHOD AND APPARATUS FOR MULTI-SLICE IMAGING OF T2-RELAXATION TIME
    Publication number: 20160139225
    Abstract: An MRI method includes performing a first image acquisition module of a pulse sequence to acquire a first MR data from slices disposed at different locations in a region of interest (ROI) of an object; performing a second image acquisition module of the pulse sequence, to acquire a second MR data from the slices disposed at the different locations of the ROI, with a T2 preparation time different than that of the first image acquisition module; and generating a T2 map based on the acquired first MR data and the acquired second MR data.
    Type: Application
    Filed: September 4, 2015
    Publication date: May 19, 2016
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Tamer BASHA, Reza NEZAFAT
  • Assays and methods of treatment relating to vitamin D insufficiency
    Patent number: 9329190
    Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: May 3, 2016
    Assignees: The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
  • BIORESORBABLE BIOPOLYMER ANASTOMOSIS DEVICES
    Publication number: 20160095599
    Abstract: A bioresorbable drug-eluting biopolymer suture-free blood vessel anastomosis devices can be deployed to join two blood vessels and resorbed by the body over a predetermined time period after the blood vessel has become joined. The anastomosis device can include a hollow tube that is inserted interconnect the two vessels to be jointed. A non-piercing suture is wrapped around the vessel to secure the anastomosis. The anastomosis device can include hollow tube that extends along an axis from a first end to a second end. The ends can be fitted with elements that facilitate mechanical attachment of the vessel to the anastomosis device and provide for a secure seal.
    Type: Application
    Filed: April 24, 2014
    Publication date: April 7, 2016
    Applicants: Trustees of Tufts College, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Rodrigo R. Jose, Waseem K. Raja, David L. Kaplan, Ahmed Ibrahim, Samuel Lin, Abdurrahman Abdurrob
  • Method for free-breathing magnetic resonance imaging using iterative image-based respiratory motion correction
    Patent number: 9271661
    Abstract: A method for free-breathing magnetic resonance imaging (MRI) using iterative image-based respiratory motion correction is provided. An MRI system is used to acquired k-space data and navigator data from a subject. The k-space data is then sorted into a plurality of data bins using the navigator data. A motion correction parameter is estimated for each data bin and is applied to the respective k-space data in that bin. The corrected k-space data segments are then combined to form a corrected k-space data set, from which an image is reconstructed. The process may be iteratively repeated until an image quality metric is optimized; for example, until an image sharpness measure is sufficiently maximized.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: March 1, 2016
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC
    Inventors: Mehdi Hedjazi Moghari, Reza Nezafat
  • miRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND THERAPY
    Publication number: 20160024503
    Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicants: Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Raghu KALLURI, Sónia MELO